期刊文献+

非复制型痘苗病毒的生物学性状研究进展 被引量:5

Research Progress of Biological Characteristics of Non- Replicating Vaccinia Viruses
下载PDF
导出
摘要 痘病毒被广泛用于针对多种感染性疾病和癌症的疫苗研究,而非复制型痘苗病毒的发展又进一步提高了其安全性。来源于中国天花疫苗株的复制缺陷型痘苗病毒天坛株(NTV)正是一株非复制型痘苗病毒。为了促进未来NTV作为疫苗候选株在临床中的应用,我们对NTV与另外2株非复制型痘苗病毒,即改良痘苗病毒安卡拉株(MVA)和NYVAC的生物学性状做简要综述,主要讨论了它们的基因组结构、体外生长特性、病毒复制和形态发生、组织中的病毒分布和病毒-宿主细胞间的相互作用。 Poxviruses have been studied extensively as vaccines against many infectious diseases and cancer, the safety of which have been enhanced through the development of non-replicating vaccinia viruses, like replication-defective vaccinia virus Tiantan(NTV), derived from a Chinese smallpox vaccine strain. To promote the use of NTV as a vaccine candidate in clinical application in the future, here we provided a review of the biological characteristics of NTV and another two non-replicating vaccinia viruses, modified vaccinia Ankara (MVA) and NYVAC. In this article we mainly discussed their genomic organization, growth characteristics in vitro, virus replication and morphogenesis, virus distribution in tissues and virus-host cell interactions.
作者 庞聪 田厚文
出处 《生物技术通讯》 CAS 2014年第3期415-420,共6页 Letters in Biotechnology
关键词 痘苗病毒天坛株 改良痘苗病毒安卡拉株 NYVAC 复制缺陷 痘病毒载体 疫苗 vaccinia virus Tiantan modified vaccinia Ankara NYVAC replication defective poxviruses vectors vaccines
  • 相关文献

参考文献41

  • 1Gomez C E, Najera G J, Krupa M, et al, MVA and NYVAC as vaccines against emergent infectious diseases and cancer [J]. Curr Gene Ther, 2011,11(3):189-217.
  • 2Pastoret P P, Vanderplasschen A. Poxviruses as vaccine vec- tors[J]. Comp Immunol Microbiol Infect Dis, 2003,26(5-6):343- 355.
  • 3Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen de- livery[J]. Curt Drug Targets Infect Disord, 2003,3(3):263-271.
  • 4Tartaglia J, Perkus M E, Taylor J, et al. NYVAC: a highly at- tenuated strain of vaccinia virus[J]. Virology, 1992,188(1):217- 232.
  • 5阮力,朱既明,娄元梅,等.复制缺陷型天坛株痘苗病毒[P].中国专利,200610056800.0,2008-06-11.
  • 6Najera J L, Gomez C E, Domingo-Gil E, et al. Cellular and biochemical differences between two attenuated poxvirus vac- cine candidates(MVA and NYVAC) and role of the C7L gene [J]. J Virol, 2006,80(12):6033-6047.
  • 7Backes S, Sperling K M, Zwilling J, et al. Viral host-range factor C7 or K1 is essential for modified vaccinia virus Anka- ra late gene expression in human and murine cells, irrespec- tive of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha [J]. J Gen Virol, 2010,91(Pt 2):470-482.
  • 8Willis K L, Patel S, Xiang Y, et al., The effect of the vaccin- ia K1 protein on the PKR-eIF2alpha pathway in RK13 and HeLa cells[J]. Virology, 2009,394(1):73-81.
  • 9Willis K L, Langland J O, Shisler J L. Viral double-stranded RNAs from vaccinia virus early or intermediate gene tran- scripts possess PKR activating function, resulting in NF-kap- paB activation, when the K1 protein is absent or mutated[J]. J Biol Chem, 2011,286(10):7765-7778.
  • 10Meng X, Jiang C, Arsenio J, et al. Vaccinia virus KIL and CTL inhibit antiviral activities induced by type I interferons [J]. J Virol, 2009,83(20):10627-10636.

二级参考文献21

  • 1杨克俭,阮力,朱诚,孙朝辉,陆柔剑,徐水婵,朱既明.同时表达麻疹病毒L4株HA和F蛋白及人白细胞介素2(IL2)的重组痘苗病毒疫苗株的构建[J].病毒学报,1996,12(4):299-306. 被引量:7
  • 2娄元梅.非复制型痘苗病毒天坛株载体的构建及其特性的研究[博士学位论文].北京:中国预防医学科学院病毒学研究所,1996..
  • 3李军.含PreS1乙肝病毒表面抗原纯化工艺的建立及生物学性质的研究[硕士学位论文].北京:中国预防医学科学学院病毒学研究所,1997..
  • 4陈南海,病毒学报,1992年,8卷,303页
  • 5黎智良,病毒学报,1989年,5卷,1页
  • 6金奇,病毒学报,1988年,4卷,285页
  • 7Yuen L,Proc Natl Acad Sci USA,1987年,84卷,6417页
  • 8侯云德,J Gen Virol,1985年,66卷,1819页
  • 9马海伦,病毒学报,1999年,15卷,21页
  • 10杨克俭,病毒学报,1996年,12卷,299页

共引文献22

同被引文献19

  • 1庞乐君,刁天喜.痘病毒疫苗载体[J].国外医学(药学分册),2004,31(3):154-157. 被引量:6
  • 2容敏清,阎辉,阮力,侯云德,何南祥,朱既明.表达HSV-2 gD基因的重组痘苗病毒保护小鼠对抗致死量HSV病霉攻击[J].病毒学报,1995,11(3):220-227. 被引量:4
  • 3Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety [ J ]. Proc Natl Acad Sci USA, 1996,93(21 ) :11341 - 11348.
  • 4Maekett M, Smith GL, Moss B. Vaccinia virus: a selectable eu- karyotic cloning and expression vector [ J ]. Proc Natl Acad Sci USA, 1982,79(23) :7415 -7419.
  • 5Gomez CE, Najera JL, Krupa M, et al. MVA and NYVAC as vac- cines against emergent infectious diseases and cancer [ J ]. Curr Gene Ther, 2011,11 (3) : 189 - 217.
  • 6Thorne SH. Immunotherapeutic potential of oncolytic vaccinia vi- rus [J]. Immunol Res, 2011,50(2 -3):286 -293.
  • 7Kristina E. Rehm,Rachel L. Roper.Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching[J].Vaccine.2011(17)
  • 8Kaifan Dai,Ying Liu,Mingjie Liu,Jianqing Xu,Wei Huang,Xianggang Huang,Lianxing Liu,Yanmin Wan,Yanling Hao,Yiming Shao.Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes[J].Vaccine.2008(39)
  • 9Patricia Nell,Katrin S. Kohl,Philip L. Graham,Philip S. LaRussa,S. Michael Marcy,Vincent A. Fulginiti,Bryan Martin,Ann McMahon,Scott A. Norton,Ingrid Trolin.Progressive vaccinia as an adverse event following exposure to vaccinia virus: Case definition and guidelines of data collection, analysis, and presentation of immunization safety data[J].Vaccine.2007(31)
  • 10张仁舟,杨松涛,夏咸柱.重组痘苗病毒载体研究进展[J].动物医学进展,2009,30(1):57-61. 被引量:5

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部